Black Diamond Therapeutics Inc’s filing revealed that its 10% Owner Versant Venture Capital VI, L. unloaded Company’s shares for reported $1.4 million on Aug 28 ’24. In the deal valued at $6.32 per share,221,600 shares were sold. As a result of this transaction, Versant Venture Capital VI, L. now holds 3,726,341 shares worth roughly $13.64 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, David Epstein bought 50,000 shares, generating $310,000 in total proceeds.
Before that, David Epstein bought 50,000 shares. Black Diamond Therapeutics Inc shares valued at $310,000 were divested by the Former Employee at a price of $6.20 per share.
Raymond James initiated its Black Diamond Therapeutics Inc [BDTX] rating to an Outperform in a research note published on July 31, 2024; the price target was $20. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in mid July with a ‘”an Overweight”‘ rating. Stifel also remained covering BDTX and has increased its forecast on June 30, 2023 with a “Buy” recommendation from previously “Hold” rating. H.C. Wainwright revised its rating on June 28, 2023. It rated BDTX as “a Buy” which previously was an “a Neutral”.
Price Performance Review of BDTX
On Monday, Black Diamond Therapeutics Inc [NASDAQ:BDTX] saw its stock fall -2.40% to $3.66. Over the last five days, the stock has lost -15.86%. Black Diamond Therapeutics Inc shares have risen nearly 30.25% since the year began. Nevertheless, the stocks have risen 45.24% over the past one year. While a 52-week high of $7.66 was reached on 05/06/24, a 52-week low of $1.62 was recorded on 01/05/24. SMA at 50 days reached $5.27, while 200 days put it at $4.86.
Levels Of Support And Resistance For BDTX Stock
The 24-hour chart illustrates a support level at 3.42, which if violated will result in even more drops to 3.19. On the upside, there is a resistance level at 3.81. A further resistance level may holdings at 3.97. The Relative Strength Index (RSI) on the 14-day chart is 31.07, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.58, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.38%. Stochastics %K at 8.50% indicates the stock is a buying.
How much short interest is there in Black Diamond Therapeutics Inc?
A steep rise in short interest was recorded in Black Diamond Therapeutics Inc stocks on 2024-09-13, dropping by -0.15 million shares to a total of 5.86 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 6.01 million shares. There was a decline of -2.64%, which implies that there is a negative sentiment for the stock.
